Primary CNS lymphoma: update on molecular pathogenesis and therapy

References

• Lv C, Wang J, Zhou M, et al. Primary Central nervous system lymphoma in the United States, 1975–2017. Ther Adv Hematol. 2022;13:20406207211066166.
   Web of Science ®Google Scholar
• Olson JE, Janney CA, Rao RD, et al. The continuing increase in the incidence of primary Central nervous system non-Hodgkin lymphoma. Cancer. 2002;95(7):1504–1510.
   PubMed Web of Science ®Google Scholar
• Schabet M. Epidemiology of primary CNS lymphoma. J Neurooncol. 1999;43(3):199–201.
   PubMed Web of Science ®Google Scholar
• Mahale P, Shiels MS, Lynch CF, et al. Incidence and outcomes of primary central nervous system lymphoma in solid organ transplant recipients. Am J Transplant. 2018;18(2):453–461.
   PubMed Web of Science ®Google Scholar
• Lai R, Rosenblum MK, DeAngelis LM. Primary CNS lymphoma: a whole-brain disease? Neurology. 2002;59(10):1557–1562.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Fridlyand J, Shen A, et al. Gene expression and angiotropism in primary CNS lymphoma. Blood. 2006;107(9):3716–3723.
   PubMed Web of Science ®Google Scholar
• Braaten KM, Betensky RA, de Leval L, et al. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res. 2003;9(3):1063–1069.
   PubMed Web of Science ®Google Scholar
• Montesinos-Rongen M, Brunn A, Bentink S, et al. Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell. Leukemia. 2008;22(2):400–405.
   PubMed Web of Science ®Google Scholar
• Mondello P, Cuzzocrea S, Arrigo C, et al. STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in primary central nervous system lymphoma. Hematol Oncol. 2020;38(1):106–110.
   PubMed Web of Science ®Google Scholar
• Sasayama T, Nakamizo S, Nishihara M, et al. Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL). Neuro Oncol. 2012;14(3):368–380.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Wong VS, Kadoch C, et al. CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood. 2013;121(23):4740–4748.
   PubMed Web of Science ®Google Scholar
• Villa D, Tan KL, Steidl C, et al. Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray. Blood Adv. 2019;3(23):3953–3961.
   PubMed Web of Science ®Google Scholar
• Kim S, Nam SJ, Kwon D, et al. MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system. BMC Cancer. 2016;16(1):363.
   PubMedGoogle Scholar
• Nakamura T, Tateishi K, Niwa T, et al. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol. 2016;42(3):279–290.
   PubMed Web of Science ®Google Scholar
• Fukumura K, Kawazu M, Kojima S, et al. Genomic characterization of primary central nervous system lymphoma. Acta Neuropathol. 2016;131(6):865–875.
   PubMed Web of Science ®Google Scholar
• Braggio E, Van Wier S, Ojha J, et al. Genome-Wide analysis uncovers novel recurrent alterations in primary Central nervous system lymphomas. Clin Cancer Res. 2015;21(17):3986–3994.
   PubMed Web of Science ®Google Scholar
• Vater I, Montesinos-Rongen M, Schlesner M, et al. The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing. Leukemia. 2015;29(3):677–685.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Aguilar A, Idbaih A, Boisselier B, et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res. 2012;18(19):5203–5211.
   PubMed Web of Science ®Google Scholar
• Chapuy B, Roemer MGM, Stewart C, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127(7):869–881.
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Hoang T, Law SC, et al. EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. Blood. 2021;137(11):1468–1477.
   PubMed Web of Science ®Google Scholar
• Nayyar N, White MD, Gill CM, et al. MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. Blood Adv. 2019;3(3):375–383.
   PubMed Web of Science ®Google Scholar
• Radke J, Ishaque N, Koll R, et al.; ICGC MMML-Seq Consortium. The genomic and transcriptional landscape of primary central nervous system lymphoma. Nat Commun. 2022;13(1):2558.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-Cell lymphoma. N Engl J Med. 2018;378(15):1396–1407.
   PubMed Web of Science ®Google Scholar
• Güney E, Lucas C-HG, Qi Z, et al. A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome. Blood Adv. 2022;6(10):3189–3193.
   PubMed Web of Science ®Google Scholar
• Geng H, Tsang M, Subbaraj L, et al. Tumor metabolism and neurocognition in CNS lymphoma. Neuro Oncol. 2021;23(10):1668–1679.
   PubMed Web of Science ®Google Scholar
• Barajas RF, Politi LS, Anzalone N, et al. Consensus recommendations for MRI and PET imaging of primary Central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neuro Oncol. 2021;23(7):1056–1071.
   PubMed Web of Science ®Google Scholar
• Margold M, Seidel S, Kowalski T, et al. The value of bone marrow biopsy for staging of patients with primary CNS lymphoma. Neuro Oncol. 2021;23(12):2076–2084.
   PubMed Web of Science ®Google Scholar
• Bobillo S, Crespo M, Escudero L, et al. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Haematologica. 2021;106(2):513–521.
   PubMed Web of Science ®Google Scholar
• Mutter JA. Profiling of circulating tumor DNA for noninvasive disease detection, risk stratification, and MRD monitoring in patients with CNS lymphoma. Proc. American Society of Hematology Annual Meeting 2021 Blood (2021) 138 (Supplement 1): 6.
   Google Scholar
• Kurtz DM, Soo J, Co Ting Keh L, et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol. 2021;39(12):1537–1547.
   PubMed Web of Science ®Google Scholar
• Tan WJ, Wang MM, Ricciardi-Castagnoli P, et al. Single-cell MYD88 sequencing of isolated B cells from vitreous biopsies aids vitreoretinal lymphoma diagnosis. Blood. 2019;134(8):709–712.
   PubMed Web of Science ®Google Scholar
• Ervin T, Canellos GP. Successful treatment of recurrent primary central nervous system lymphoma with high-dose methotrexate. Cancer. 1980;45(7):1556–1557.
   PubMed Web of Science ®Google Scholar
• Skarin AT, Zuckerman KS, Pitman SW, et al. High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. Blood. 1977;50(6):1039–1047.
   PubMed Web of Science ®Google Scholar
• Thomas S, Fisher KH, Snowden JA, et al. Methotrexate is a JAK/STAT pathway inhibitor. PLoS One. 2015;10(7):e0130078.
   PubMed Web of Science ®Google Scholar
• Majumdar S, Aggarwal BB. Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation. J Immunol. 2001;167(5):2911–2920.
   PubMed Web of Science ®Google Scholar
• DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary Central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002;20(24):4643–4648.
   PubMed Web of Science ®Google Scholar
• Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23(1):9–17.
   PubMed Web of Science ®Google Scholar
• Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol. 1998;16(3):859–863.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Cwynarski K, Pulczynski E, et al.; International Extranodal Lymphoma Study Group (IELSG). Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3(5):e217–e227.
   PubMed Web of Science ®Google Scholar
• Bromberg JEC, Issa S, Bakunina K, et al. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2019;20(2):216–228.
   PubMed Web of Science ®Google Scholar
• Schmitt AM, Herbrand AK, Fox CP, et al. Rituximab in primary central nervous system lymphoma—a systematic review and meta-analysis. Hematol Oncol. 2019;37(5):548–557.
   PubMed Web of Science ®Google Scholar
• DeAngelis LM, Yahalom J, Thaler HT, et al. Combined modality therapy for primary CNS lymphoma. J Clin Oncol. 1992;10(4):635–643.
   PubMed Web of Science ®Google Scholar
• Morris PG, Correa DD, Yahalom J, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31(31):3971–3979.
   PubMed Web of Science ®Google Scholar
• Omuro AMP, DeAngelis LM, Karrison T, NRG, et al. Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL). J Clin Oncol. 2020;38(15_suppl):2501–2501.
   Web of Science ®Google Scholar
• Wieduwilt MJ, Valles F, Issa S, et al. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res. 2012;18(4):1146–1155.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013;31(25):3061–3068.
   PubMed Web of Science ®Google Scholar
• Birsen R, Willems L, Pallud J, et al. Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary Central nervous system lymphoma in immunocompetent patients. Haematologica. 2018;103(7):e296–e299.
   PubMed Web of Science ®Google Scholar
• Omuro A, Correa DD, DeAngelis LM, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125(9):1403–1410.
   PubMed Web of Science ®Google Scholar
• Illerhaus G, Kasenda B, Ihorst G, et al. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematol. 2016;3(8):e388-397–e397.
   Web of Science ®Google Scholar
• Houillier C, Taillandier L, Dureau S, et al.; Intergroupe GOELAMS–ANOCEF and the LOC Network for CNS Lymphoma. Radiotherapy or autologous Stem-Cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. J Clin Oncol. 2019;37(10):823–833.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Cwynarski K, Pulczynski E, et al.; International Extranodal Lymphoma Study Group (IELSG). Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017;4(11):e510–e523.
   PubMed Web of Science ®Google Scholar
• Scordo M, Wang TP, Ahn KW, et al. Outcomes associated with thiotepa-based conditioning in patients with primary central nervous system lymphoma after autologous hematopoietic cell transplant. JAMA Oncol. 2021;7(7):993–1003.
   PubMed Web of Science ®Google Scholar
• Batchelor T, Giri S, Ruppert AS, et al. Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: results of CALGB 51101 (Alliance). J Clin Oncol. 2021;39(15_suppl):7506–7506.
   Web of Science ®Google Scholar
• Omuro A, Chinot O, Taillandier L, et al. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol. 2015;2(6):e251-259–e259.
   Web of Science ®Google Scholar
• Rubenstein JL, Geng H, Fraser EJ, et al. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv. 2018;2(13):1595–1607.
   PubMed Web of Science ®Google Scholar
• Vu K, Mannis G, Hwang J, et al. Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma. Br J Haematol. 2019;186(1):180–183.
   PubMed Web of Science ®Google Scholar
• Ghesquieres H, Chevrier M, Laadhari M, et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA). Ann Oncol. 2019;30(4):621–628.
   PubMed Web of Science ®Google Scholar
• Tun HW, Johnston PB, DeAngelis LM, et al. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. Blood. 2018;132(21):2240–2248.
   PubMed Web of Science ®Google Scholar
• Carpio C, Bouabdallah R, Ysebaert L, et al. Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier. Blood. 2020;135(13):996–1007.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute (NCI). 2022. Phase I trial of methotrexate, rituximab, lenalidomide, and nivolumab (Nivo-MR2) induction followed by lenalidomide and nivolumab maintenance in primary CNS lymphoma. (NCT04609046).
   Google Scholar
• Zinzani PL, Rodgers T, Marino D, et al. RE-MIND: comparing tafasitamab + lenalidomide (L-MIND) with a real-world lenalidomide monotherapy cohort in relapsed or refractory diffuse large B-cell lymphoma. Clin Cancer Res. 2021;27(22):6124–6134.
   PubMed Web of Science ®Google Scholar
• Grommes C, Pastore A, Palaskas N, et al. Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017;7(9):1018–1029.
   PubMed Web of Science ®Google Scholar
• Soussain C, Choquet S, Blonski M, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II ‘proof-of-concept’ iLOC study by the lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. Eur J Cancer. 2019;117:121–130.
   PubMed Web of Science ®Google Scholar
• Grommes C, Tang SS, Wolfe J, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood. 2019;133(5):436–445.
   PubMed Web of Science ®Google Scholar
• Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31(6):833–843.e5.
   PubMed Web of Science ®Google Scholar
• Narita Y, Nagane M, Mishima K, et al. Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary Central nervous system lymphoma. Neuro Oncol. 2021;23(1):122–133.
   PubMed Web of Science ®Google Scholar
• Nayak L, Iwamoto FM, LaCasce A, et al. PD-1 blockade with nivolumab in relapsed/refractory primary Central nervous system and testicular lymphoma. Blood. 2017;129(23):3071–3073.
   PubMed Web of Science ®Google Scholar
• Ambady P, Szidonya L, Firkins J, et al. Combination immunotherapy as a non-chemotherapy alternative for refractory or recurrent CNS lymphoma. Leuk Lymphoma. 2019;60(2):515–518.
   PubMed Web of Science ®Google Scholar
• Hoang-Xuan K, Houot R, Soussain C, et al. First results of the acsé pembrolizumab phase II in the primary CNS lymphoma (PCNSL) cohort. Blood. 2020;136(Supplement 1):15–16.
   Google Scholar
• Nayak L, Iwamoto FM, Ferreri AJ, et al. Checkmate 647: a phase 2, Open-Label study of nivolumab in relapsed/refractory primary Central nervous system lymphoma or relapsed/refractory primary testicular lymphoma. Hematol Oncol. 2017;35:420–421.
   PubMedGoogle Scholar
• Siddiqi T, Wang X, Blanchard MS, et al. CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. Blood Adv. 2021;5(20):4059–4063.
   PubMed Web of Science ®Google Scholar
• Frigault MJ, Dietrich J, Gallagher K, et al. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood. 2022;139(15):2306–2315.
   PubMed Web of Science ®Google Scholar
• van der Meulen M, Dirven L, Bakunina K, et al. MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma. J Neurooncol. 2021;152(2):357–362.
   PubMed Web of Science ®Google Scholar